 Earlier today, Ultragenyx Pharmaceutical Inc NASDAQ: RARE released updated interim GTX-102 data, including Day 128 assessments from 9 patients. The Overall CGI-C-AS score improved by 1 point in 56 patients average 0.8 in Cohort 4 and 1 point in 23 patients average 0.7. 